Clinical Trial Update: Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial comparing alemtuzumab to anti-thymocyte globulin for prevention of graft rejection in kidney and pancreas transplantation; completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection
• Pancreas Transplant Rejection

Drugs mentioned

• alegtuzumab (alemtuzumab)
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Graft Rejection | Phase 4 | Status: COMPLETED | Results posted: 2018-06-06